Navigation Links
Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer

MALVERN, Pa., May 31, 2011 /PRNewswire/ -- Fujirebio Diagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ EIA assay to monitor disease progression during the course of disease and treatment of lung cancer patients. This is the first biomarker assay kit to be cleared by FDA for use in the management of patients with lung cancer.

"The clearance of the CYFRA 21-1 assay kit adds to Fujirebio's growing portfolio of tumor marker assays for ovarian cancer, pancreatic cancer, breast cancer, and other malignancies," commented Monte Wiltse, Vice President of Sales and Marketing at Fujirebio Diagnostics. "Achieving FDA clearance of the CYFRA 21-1 assay kit for lung cancer is the first step in what we anticipate will be a strong pipeline of innovations that help physicians in the management of lung cancer."

The CYFRA 21-1 assay kit is indicated for the quantitative determination of soluble cytokeratin 19 fragments in human serum. It is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with lung cancer. Serial testing for patient CYFRA 21-1 assay values should be used in conjunction with other clinical methods used for monitoring lung cancer. Data submitted to FDA showed that changes in CYFRA 21-1 values correlated with changes in disease status in 76% of the studied patient population.

According to the Surveillance Epidemiology and End Results (SEER) database of the National Cancer Institute (NCI), an estimated 222,520 new cases of lung cancer were diagnosed in the U.S. in 2010, and roughly 157,300 Americans died of the disease.(1)

"FDA clearance of CYFRA 21-1 allows laboratories in the US the opportunity to provide a valuable diagnostic tool to oncologists in the management of lung cancer," said David Grenache, PhD, a Medical Director at ARUP Laboratories in Salt Lake City, UT. "ARUP Laboratories is pleased to offer the first ever FDA cleared biomarker for lung cancer to physicians in the US."

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings, Inc., in Japan, set up in July 2005 to combine Fujirebio Inc., the leading in-vitro diagnostics company, and SRL, Inc., the top provider of clinical laboratory testing services in Japan. Fujirebio Diagnostics has a worldwide distribution network, which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call 610-240-3800 or visit

(1)  Altekruse SF, Kosary CL, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2007., based on November 2009 SEER data submission. Bethesda, MD: National Cancer Institute. Posted to the SEER Web site, 2010.  Accessed September 27, 2010.

SOURCE Fujirebio Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fujirebio Diagnostics Named Life Sciences Company of the Year
2. Siemens Showcases New Innovations in Clinical Diagnostics, Automation, and IT at IFCC-WorldLab Berlin 2011
3. Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference
4. OnPoint Medical Diagnostics, Inc. and Vertical Health Solutions, Inc. Complete Reverse Merger
5. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
6. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
7. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
8. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting
9. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
10. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
11. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
Post Your Comments:
(Date:11/30/2015)... 2015  Precision Image Analysis Inc. (PIA), a ... announce a dramatic expansion of its capabilities as ... its ISO-9001:2008 certification for its Quality Management System, ... protocols and procedures. This expansion enables PIA to ... Core Lab services include design and optimization of ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 ... . --> Pharmaboardroom releases its new 98-page Mexico ... America , a country of over 122 million people. ... 122 million people. --> It offers companies, investors, policymakers, ... insights into the second largest pharma and healthcare market in ...
(Date:11/30/2015)... AVIV, Israel , November 30, 2015 ... ) ("Elbit" or the "Company") announced today that it was ... of Food and Drug Safety (MFDS) has approved its ... disorders. --> --> ... a non-invasive treatment alternative that combines two technologies: Focused ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
(Date:11/30/2015)... ... 30, 2015 , ... While powdered supplements and drinks can reduce food preparation ... from Chesterfield, Va., has found an easy to keep track of the scoop. , ... powdered contents in a canister or other container handy and readily accessible. As such, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since ... websites specializing in independent living, assisted living and all other retirement options. Support ... awareness and research remains a top priority. , So it’s no ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
Breaking Medicine News(10 mins):